We are live on
!
Find out more
Jacobs Levy Equity Management Portfolio holdings
AUM
$23.8B
1-Year Est. Return
25.4%
This Fund
S&P 500
This Quarter
Est. Return
+7.34%
1 Year Est. Return
+25.4%
3 Year Est. Return
+87.35%
5 Year Est. Return
+125.75%
10 Year Est. Return
+515.94%
AUM
$14.8B
AUM Growth
+$2.13B
(+17%)
Cap. Flow
+$1.52B
Cap. Flow
% of AUM
10.28%
Top 10 Holdings %
Top 10 Hldgs %
17.14%
Holding
1,089
New
119
Increased
321
Reduced
473
Closed
155
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Vertex Pharmaceuticals
VRTX
|
+$132M |
| 2 |
Apple
AAPL
|
+$117M |
| 3 |
Microsoft
MSFT
|
+$100M |
| 4 |
Fidelity National Information Services
FIS
|
+$94.3M |
| 5 |
FedEx
FDX
|
+$91.4M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Cigna
CI
|
+$97.2M |
| 2 |
Booking.com
BKNG
|
+$94.2M |
| 3 |
Phillips 66
PSX
|
+$82.9M |
| 4 |
Gilead Sciences
GILD
|
+$73.9M |
| 5 |
Snowflake
SNOW
|
+$51.2M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 26.09% |
| 2 | Financials | 15.5% |
| 3 | Healthcare | 14.12% |
| 4 | Consumer Discretionary | 11.36% |
| 5 | Industrials | 9.8% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
FSFG
901
DELISTED
First Savings Financial Group
FSFG
| $214K | ﹤0.01% |
10,677
-6,465
| -38% | -$144K |
|
902
Root
ROOT
$972M
| $209K | ﹤0.01% |
46,627
-2,704
| -5% | -$18.6K |
|
903
Werewolf Therapeutics
HOWL
$21.8M
| $208K | ﹤0.01% |
+101,221
| New | +$265K |
|
904
Exelon
EXC
$48.4B
| $206K | ﹤0.01% |
+4,775
| New | +$189K |
|
905
Greenlight Captial
GLRE
$586M
| $206K | ﹤0.01% |
25,290
-38,091
| -60% | -$297K |
|
906
Business First Bancshares
BFST
$1.05B
| $204K | ﹤0.01% |
9,234
-431
| -4% | -$9.89K |
|
907
Biglari Holdings Class B
BH
$1.18B
| $201K | ﹤0.01% |
+1,451
| New | +$199K |
|
908
American Realty Investors
ARL
$241M
| $201K | ﹤0.01% |
+7,844
| New | +$157K |
|
909
Bank of N.T. Butterfield & Son
NTB
$2.37B
| $200K | ﹤0.01% |
6,721
-23
| -0.3% | -$760 |
|
910
Cue Biopharma
CUE
$127M
| $198K | ﹤0.01% |
+2,317
| New | +$212K |
|
911
Tenaya Therapeutics
TNYA
$164M
| $196K | ﹤0.01% |
97,631
-159,004
| -62% | -$388K |
|
912
KVH Industries
KVHI
$172M
| $191K | ﹤0.01% |
18,642
-53,650
| -74% | -$545K |
|
913
Rapid Micro Biosystems
RPID
$103M
| $182K | ﹤0.01% |
+161,400
| New | +$391K |
|
914
Caesarstone
CSTE
$71.6M
| $179K | ﹤0.01% |
+31,303
| New | +$234K |
|
915
Lands' End
LE
$389M
| $166K | ﹤0.01% |
+21,900
| New | +$201K |
|
916
Aldeyra Therapeutics
ALDX
$95.3M
| $149K | ﹤0.01% |
21,374
-260,462
| -92% | -$1.49M |
|
917
Noodles & Co
NDLS
$88.2M
| $149K | ﹤0.01% |
3,386
-697
| -17% | -$30.6K |
|
918
American Outdoor Brands
AOUT
$159M
| $146K | ﹤0.01% |
14,620
-113,825
| -89% | -$1.06M |
|
|
HRT
919
DELISTED
HireRight Holdings Corporation
HRT
| $144K | ﹤0.01% |
+12,143
| New | +$151K |
|
920
Vaalco Energy
EGY
$540M
| $137K | ﹤0.01% |
30,112
-100,900
| -77% | -$507K |
|
921
Editas Medicine
EDIT
$402M
| $134K | ﹤0.01% |
15,103
-92,035
| -86% | -$1.01M |
|
|
CCC
922
CCC Intelligent Solutions
CCC
$3.59B
| $131K | ﹤0.01% |
15,007
-555,818
| -97% | -$4.95M |
|
923
Olema Pharmaceuticals
OLMA
$1.01B
| $127K | ﹤0.01% |
51,828
-28,091
| -35% | -$81.9K |
|
924
Cooper-Standard Automotive
CPS
$526M
| $122K | ﹤0.01% |
13,508
-89,084
| -87% | -$631K |
|
925
Verastem
VSTM
$547M
| $118K | ﹤0.01% |
24,361
-7,199
| -23% | -$35.3K |
|
Similar funds
OAG
CHP
SAM
JG
Jacobs Levy Equity Management's Q4 2022 Portfolio in Review
As of Q4 2022, Jacobs Levy Equity Management held 1,089 positions worth $14.8B, up 17% from $12.6B the previous quarter. Its ten largest holdings account for 17% of the portfolio.
Jacobs Levy Equity Management deployed $1.52B of net new capital in Q4 2022, opening 119 new positions and adding to 321 existing holdings. Its largest new stake was Fidelity National Information Services: 1,326,663 shares worth $90M.
By sector, the portfolio is most concentrated in Technology at 26% of assets, up from 26% a quarter earlier, followed by Financials and Healthcare.
On the sell side, the largest reduction was Booking.com, an estimated $94.2M trimmed.
- Jacobs Levy Equity Management's largest Q4 2022 buy was Fidelity National Information Services: 1,326,663 shares worth $90M.
- Jacobs Levy Equity Management added most to Vertex Pharmaceuticals in Q4 2022, an estimated $132M increase.
- Jacobs Levy Equity Management's biggest Q4 2022 reduction was Booking.com, cutting an estimated $94.2M.
- Jacobs Levy Equity Management fully exited Cigna in Q4 2022, selling an estimated $97.2M.
- Jacobs Levy Equity Management's ten largest holdings make up 17% of its $14.8B portfolio in Q4 2022.
- Jacobs Levy Equity Management opened 119 new positions and closed 155 in Q4 2022.
- Jacobs Levy Equity Management's portfolio value rose 17% quarter-over-quarter to $14.8B.
Based on Jacobs Levy Equity Management's 13F filing for Q4 2022, filed 14 Feb 2023.